TICKERNERD
Menu
CVSAConsumer Defensive · Education & Training Services

CVSA Stock Forecast: Covista, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$133
+0.31% on the day

The 4 Wall Street analysts covering Covista, Inc. hold a median 12-month price target of $162 — +21.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$4.5B
Ticker Nerd rank
79 / 100
Median analyst target
$162
Analysts covering
4
Revenue$501.4M+9.7% y/y
Operating income$96.5M
Net income$71.7M
Free cash flow$97.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
+14.6%
YTD
+28.3%
1Y
−1.6%
From 52W high
−14.0%
From 52W low
+48.6%
$89
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Covista, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Quality
82
Issuance
64
Value
63
Accruals
63
Momentum
61
Growth
49
Volatility
45
Size
25

Revisions (92): Analysts have, on balance, been raising their forecasts.

Volatility (45): The share price moves around a lot.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160$180Oct 25Jan 26Apr 26Jul 26CVSAHigh $175Median $162Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $140Median $162High $175

The green dot is the last close — the median target sits +21.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 June 2026Barrington ResearchMaintainsOutperform$170
11 May 2026Truist SecuritiesMaintainsBuy—
17 Apr 2026Barrington ResearchMaintainsOutperform—
24 Mar 2026Truist SecuritiesInitiatesBuy—
2 Mar 2026Barrington ResearchMaintainsOutperform—
29 Jan 2026Barrington ResearchMaintainsOutperform—
31 Oct 2025Barrington ResearchMaintainsOutperform—
15 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
8 Aug 2025Barrington ResearchMaintainsOutperform$140 → $150
30 July 2025Barrington ResearchMaintainsOutperform$140
12 May 2025BMO CapitalMaintainsOutperform$115 → $132
9 May 2025Barrington ResearchMaintainsOutperform$120 → $140
23 Apr 2025JefferiesInitiatesBuy$135
15 Apr 2025Barrington ResearchMaintainsOutperform$120
3 Feb 2025BMO CapitalMaintainsOutperform$108 → $115
31 Jan 2025Barrington ResearchMaintainsOutperform$115 → $120
17 Jan 2025Barrington ResearchMaintainsOutperform$95 → $115
30 Oct 2024Barrington ResearchMaintainsOutperform$90 → $95
30 Oct 2024BMO CapitalMaintainsOutperform$84 → $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CVSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Covista, Inc. returned −1.6% against +19.6% for the S&P 500, dividends included.

CVSA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26CVSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.7%
Analysts raising
2
Analysts cutting
1
Fundamentals

Covista, Inc. (CVSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.7×

Cheaper than 43% of US stocks

Price / sales
2.3×

Cheaper than 50% of US stocks

Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
11.3×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 51% of US stocks

Earnings growth (YoY)
32.3%

Higher than 68% of US stocks

Gross margin
56.8%

Higher than 70% of US stocks

Operating margin
19.3%

Higher than 78% of US stocks

Net margin
12.9%

Higher than 75% of US stocks

Returns & dividend
Return on equity
18.6%

Higher than 80% of US stocks

Return on assets
8.5%

Higher than 89% of US stocks

Dividend yield
0.3%

Higher than 5% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Covista, Inc. (CVSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Covista, Inc. has a market value of $4.5B and an enterprise value of $5.0B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: $251.6M, a 12.9% net margin.

  • Diluted earnings per share, trailing twelve months: $7.04.

  • Free cash flow in the twelve months to 30 June 2026: $392.7M, after $77.7M of capital spending.

  • Covista, Inc. spent $239.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 34.0M.

  • Trailing P/E: 17.7×; forward P/E: 13.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.27%, paying out 0% of earnings.

  • Covista, Inc. employs 4,736 people — $413K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

CVSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelEducation & Training Services
CompanyMarket capTKN rank
CVSACovista, Inc.$4.5B
79
XXITwenty One Capital, Inc.$4.2B
2
LAURLaureate Education, Inc.$5.2B
81
LOPEGrand Canyon Education, Inc.$3.9B
73
LRNStride, Inc.$3.5B
62
MHMcGraw Hill, Inc.$2.5B
56
PRDOPerdoceo Education Corp.$2.1B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Covista, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVSA news & analysis

Here's Why Covista (CVSA) is a Strong Growth Stock

Zacks Investment Research · 17 Aug 2026positive

Zacks Investment Research published an article titled "Here's Why Covista (CVSA) is a Strong Growth Stock," pointing to the Zacks Style Scores as a tool for identifying market-beating stocks for investment portfolios. The item highlights Covista as a strong growth stock candidate.

Why it matters — CVSA watchers would care because the item frames the company as a strong growth stock identified through Zacks' stock-selection methodology.

Covista: Strong Secular Growth And Operating Leverage

Seeking Alpha · 14 Aug 2026positive

Seeking Alpha rated Covista a BUY, citing secular healthcare education demand and 12 consecutive quarters of enrollment growth. The company reported Q4 revenue up 9.7% and adjusted EPS up 25.9%, with all segments showing margin expansion and positive operating leverage.

Why it matters — A CVSA watcher would care because the article highlights sustained enrollment growth, strong operating leverage, and significant share repurchases, all pointing to improving financial health and shareholder returns.

Covista SVP Sells 4,526 Shares for $615,000

The Motley Fool · 13 Aug 2026negative

On August 7, 2026, Covista (CVSA) Senior Vice President sold 4,526 shares for approximately $615,000, reducing the insider's direct equity holdings by 14%.

Why it matters — A CVSA watcher would care because a significant insider sale reducing direct holdings can signal insider sentiment about the company's outlook.

Why Covista (CVSA) is a Top Value Stock for the Long-Term

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research published an article highlighting Covista (CVSA) as a top value stock for the long term. The article points to the Zacks Style Scores as a tool for selecting strong, market-beating stocks.

Why it matters — A CVSA watcher would care because a major research firm is publicly characterizing the company as a strong long-term value pick.

Covista Q4 Earnings & Revenues Top Estimates, Enrollments Up Y/Y

Zacks Investment Research · 7 Aug 2026positive

Covista (CVSA) reported fourth-quarter earnings and revenues that topped estimates, with double-digit profit growth and record Walden enrollment. The company also raised its fiscal 2027 targets, citing strong execution across all three segments.

Why it matters — CVSA watchers would care because the company beat expectations, achieved record enrollment, and raised its fiscal 2027 guidance, signaling continued strong operational momentum.

FAQ

Frequently asked questions about CVSA stock

What is the CVSA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Covista, Inc. have a median 12-month price target of $162, with estimates ranging from $140 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVSA stock a buy right now?

Of the 4 analysts covering Covista, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Covista, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVSA?

As at 22 Aug 2026, Covista, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will CVSA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +21.6% from the last close, and Ticker Nerd's factor model ranks Covista, Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVSA stock forecast for 2030?

No analyst covering Covista, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $175 over the next 12 months.

How has CVSA stock performed over the past year?

Covista, Inc. returned -1.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Covista, Inc. do?

Adtalem Global Education Inc. is a premier educational services company focused on empowering students to achieve their academic and career goals.

What is the latest news on CVSA?

The most recent item we track (Zacks Investment Research, 17 Aug 2026): "Here's Why Covista (CVSA) is a Strong Growth Stock". Zacks Investment Research published an article titled "Here's Why Covista (CVSA) is a Strong Growth Stock," pointing to the Zacks Style Scores as a tool for identifying market-beating stocks for investment portfolios. The item highlights Covista as a strong growth stock candidate.

Company

About Covista, Inc.

Adtalem Global Education Inc. is a premier educational services company focused on empowering students to achieve their academic and career goals. Specializing in providing undergraduate, graduate, and professional degrees, Adtalem operates through a network of institutions and is involved in various sectors, including healthcare, business management, and legal education. The organization is committed to increasing access to educational opportunities, equipping students with the skills necessary for a global workforce. Noteworthy institutions under the Adtalem umbrella include the Chamberlain University, known for its nursing programs, and the Ross University School of Medicine, supporting medical education. Through these entities, Adtalem not only addresses the significant demand for skilled professionals but also contributes to societal needs with its healthcare and business-oriented programs. Adtalem plays a critical role in the financial market by catering to an ever-present need for professional education, aligning with industry requirements and workforce development trends. As the demand for qualified professionals continues to rise, Adtalem's strategic positioning in the education sector underscores its importance and resilience in the market.

CEO Mr. Stephen W. Beard J.D. · 4,736 employees · United States · https://www.covista.com